SCHEMBL4209494

SCHEMBL4209494

CC(=O)OCCOc1ccc(Cl)cc1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 3/20 0.47
PKM P14618 1/20 0.47
MAPT P10636 4/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
S1PR4 O95977 2/20 0.44
ERN1 O75460 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3362167 0.84 SRC (0.45) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL29135033 0.83 MAPT (0.60) ALDH1A1MAPTHPGDTSHRS1PR4
SCHEMBL29189167 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EPKMMAPTHPGD
SCHEMBL30304244 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EPKMMAPTHPGD
SCHEMBL14785176 0.80 KMT2A (0.56) ALDH1A1KDM4EPKMMAPTMEN1
SCHEMBL30902395 0.80 ERN1 (0.50) ALDH1A1KDM4EPKMMAPTMEN1
SCHEMBL5882305 0.80 ERN1 (0.50) ALDH1A1KDM4EPKMMAPTMEN1
SCHEMBL18114753 0.80 KDM4E (0.53) ALDH1A1KDM4EPKMMAPTMEN1
SCHEMBL30304115 0.80 KMT2A (0.56) ALDH1A1KDM4EPKMMAPTMEN1
SCHEMBL4209039 0.78 KDM4E (0.51) ALDH1A1KDM4EPKMMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES RB1, PKD1, KRAS ALDH1A1 156/4885KDM4E 2117/4885PKM 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.